









Markets
/
Stocks
/
nasdaq-abbv
/

AbbVie Inc

ABBV

227.477USD

+1.837+0.81%

Market hours （ET）Quotes delayed by 15 min

402.03BMarket Cap

171.38P/E TTM



AbbVie Inc

227.477

+1.837+0.81%

Overview Financials Analysis Company

Overview

Financials

Analysis

Company

More Details of AbbVie Inc Company

AbbVie Inc. is an American pharmaceutical firm based in North Chicago, Illinois. Its prominent products include Humira, which is approved for treating autoimmune diseases such as rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis, and is administered through injection; Skyrizi, an interleukin-23 inhibitor also aimed at treating autoimmune disorders; Rinvoq, utilized for arthritis management; and Botox. Other significant offerings comprise Imbruvica for cancer treatment, Vraylar for schizophrenia and bipolar disorder, Venclexta for leukemia and lymphoma, and Mavyret for Hepatitis C treatment. The company is also dedicated to advancing therapies for additional conditions such as cancer, neurologic diseases, eye care, and cystic fibrosis.

AbbVie is ranked sixth among the largest biomedical companies by revenue and holds the 108th position on the Forbes Global 2000 list.

The name "AbbVie" originates from a combination of "Abbott," the name of its former parent company, and "vie," which refers to a Latin root meaning 'life.'

AbbVie Inc Info



Ticker SymbolABBV

Company nameAbbVie Inc

IPO dateJan 02, 2013

CEOMichael (Robert A)

Number of employees55000

Security typeOrdinary Share

Fiscal year-endJan 02

Address1 N Waukegan Rd

CityNORTH CHICAGO

Stock exchangeNASDAQ OMX NASDAQ Basic NYSE

CountryUnited States of America

Postal code60064

Phone18479327900

Websitehttps://www.abbvie.com/

Ticker SymbolABBV

IPO dateJan 02, 2013

CEOMichael (Robert A)

Company Executives of AbbVie Inc



Name

Name/Position

Position

Shareholding

Change

Dr. Azita Saleki-Gerhardt, Ph.D.

Executive Vice President, Chief Operations Officer

183.77K

Mr. Thomas C. (Tom) Freyman, CPA

Independent Director

134.63K

+1203.00%

Mr. Edward J. (Ed) Rapp

Independent Director

42.95K

+1203.00%

Dr. Roopal Thakkar, M.D.

Executive Vice President - Research & Development, Chief Scientific Officer

42.28K

+5877.00%

Ms. Roxanne S. Austin, CPA

Lead Independent Director

38.46K

+1203.00%

Dr. Robert J. Alpern, M.D.

Independent Director

35.65K

+1203.00%

Mr. Frederick H. (Rick) Waddell

Independent Director

28.96K

+1203.00%

Ms. Melody B. Meyer

Independent Director

16.50K

+1203.00%

Mr. Timothy J. Richmond

Chief Human Resources Officer, Executive Vice President

6.13K

-21250.00%

Ms. Jennifer L. Davis

Independent Director

2.52K

+1203.00%

Name

Name/Position

Position

Shareholding

Change

Dr. Azita Saleki-Gerhardt, Ph.D.

Executive Vice President, Chief Operations Officer

183.77K

Mr. Thomas C. (Tom) Freyman, CPA

Independent Director

134.63K

+1203.00%

Mr. Edward J. (Ed) Rapp

Independent Director

42.95K

+1203.00%

Dr. Roopal Thakkar, M.D.

Executive Vice President - Research & Development, Chief Scientific Officer

42.28K

+5877.00%

Ms. Roxanne S. Austin, CPA

Lead Independent Director

38.46K

+1203.00%

Dr. Robert J. Alpern, M.D.

Independent Director

35.65K

+1203.00%

Revenue Breakdown

Currency: USDUpdated: Tue, Jan 6

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

By BusinessUSD

Name

Revenue

Proportion

Immunology-SKYRIZI

4.71B

29.84%

Immunology-RINVOQ

2.18B

13.84%

Immunology-HUMIRA

993.00M

6.29%

Neuroscience-Botox Therapeutic

985.00M

6.24%

Neuroscience-Vraylar

934.00M

5.92%

Other

5.97B

37.85%

By RegionUSD

Name

Revenue

Proportion

United States

11.53B

73.07%

International

3.35B

21.21%

All other countries

660.00M

4.18%

Collaboration revenue

243.00M

1.54%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Immunology-SKYRIZI

4.71B

29.84%

Immunology-RINVOQ

2.18B

13.84%

Immunology-HUMIRA

993.00M

6.29%

Neuroscience-Botox Therapeutic

985.00M

6.24%

Neuroscience-Vraylar

934.00M

5.92%

Other

5.97B

37.85%

Shareholding Stats

Updated: Sun, Nov 16

Shareholders

Shareholder Types

Shareholders

Proportion

The Vanguard Group, Inc.

10.18%

BlackRock Institutional Trust Company, N.A.

5.25%

State Street Investment Management (US)

4.52%

Geode Capital Management, L.L.C.

2.29%

JP Morgan Asset Management

2.06%

Other

75.70%

Shareholders

Proportion

The Vanguard Group, Inc.

10.18%

BlackRock Institutional Trust Company, N.A.

5.25%

State Street Investment Management (US)

4.52%

Geode Capital Management, L.L.C.

2.29%

JP Morgan Asset Management

2.06%

Other

75.70%

Shareholder Types

Shareholders

Proportion

Investment Advisor

43.82%

Investment Advisor/Hedge Fund

20.47%

Research Firm

3.08%

Bank and Trust

2.30%

Pension Fund

2.27%

Sovereign Wealth Fund

1.41%

Hedge Fund

0.92%

Insurance Company

0.70%

Family Office

0.20%

Other

24.83%

Institutional Shareholding



Updated: Mon, Dec 8

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q4

5311

1.33B

74.86%

+1.37M

2025Q3

5386

1.32B

74.95%

+8.86M

2025Q2

5326

1.32B

74.78%

+2.41M

2025Q1

5334

1.32B

74.15%

+3.84M

2024Q4

5267

1.31B

73.92%

+9.35M

2024Q3

4970

1.30B

74.13%

-1.24M

2024Q2

4907

1.30B

73.33%

+14.47M

2024Q1

4916

1.28B

72.48%

+1.37M

2023Q4

4861

1.27B

72.12%

+10.24M

2023Q3

4666

1.27B

72.28%

+8.75M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

The Vanguard Group, Inc.

176.93M

10.01%

+427.57K

+0.24%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

92.78M

5.25%

+679.67K

+0.74%

Sep 30, 2025

State Street Investment Management (US)

79.82M

4.52%

-202.47K

-0.25%

Sep 30, 2025

Geode Capital Management, L.L.C.

40.44M

2.29%

+1.26M

+3.22%

Sep 30, 2025

JP Morgan Asset Management

36.42M

2.06%

-1.05M

-2.81%

Sep 30, 2025

Charles Schwab Investment Management, Inc.

25.96M

1.47%

-825.22K

-3.08%

Sep 30, 2025

Capital Research Global Investors

25.23M

1.43%

-34.75K

-0.14%

Sep 30, 2025

Morgan Stanley Smith Barney LLC

23.97M

1.36%

+460.64K

+1.96%

Sep 30, 2025

Norges Bank Investment Management (NBIM)

23.10M

1.31%

-1.99M

-7.94%

Jun 30, 2025

Fidelity Management & Research Company LLC

19.95M

1.13%

+301.27K

+1.53%

Sep 30, 2025

Related ETFs



Updated: Sat, Dec 6

Name

Proportion

VanEck Pharmaceutical ETF

9.64%

First Trust NASDAQ Pharmaceuticals ETF

8.05%

Health Care Select Sector SPDR Fund

7.89%

Proshares Ultra Health Care

7.62%

iShares U.S. Healthcare ETF

7.57%

JPMorgan Healthcare Leaders ETF

6.87%

Simplify Health Care ETF

6.73%

Fidelity MSCI Health Care Index ETF

6.5%

Harbor Health Care ETF

6.18%

iShares Core High Dividend ETF

5.9%

VanEck Pharmaceutical ETF

Proportion9.64%

First Trust NASDAQ Pharmaceuticals ETF

Proportion8.05%

Health Care Select Sector SPDR Fund

Proportion7.89%

Proshares Ultra Health Care

Proportion7.62%

iShares U.S. Healthcare ETF

Proportion7.57%

JPMorgan Healthcare Leaders ETF

Proportion6.87%

Simplify Health Care ETF

Proportion6.73%

Fidelity MSCI Health Care Index ETF

Proportion6.5%

Harbor Health Care ETF

Proportion6.18%

iShares Core High Dividend ETF

Proportion5.9%

Dividend



A total of 40.87B USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

Oct 31, 2025

ABBV.NB Interim Cash Dividend of gross USD 1.73 paid on Feb 17, 2026 going ex on Jan 16, 2026 with reinvestment option

Jan 16, 2026

Feb 17, 2026

Jan 16, 2026

Sep 05, 2025

ABBV.NB Final Cash Dividend of gross USD 1.64 paid on Nov 14, 2025 going ex on Oct 15, 2025 with reinvestment option

Oct 15, 2025

Nov 14, 2025

Oct 15, 2025

Jun 20, 2025

ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on Aug 15, 2025 going ex on Jul 15, 2025 with reinvestment option

Jul 15, 2025

Aug 15, 2025

Jul 15, 2025

Feb 13, 2025

ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on May 15, 2025 going ex on Apr 15, 2025 with reinvestment option

Apr 15, 2025

May 15, 2025

Apr 15, 2025

Oct 30, 2024

ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on Feb 14, 2025 going ex on Jan 15, 2025 with reinvestment option

Jan 15, 2025

Feb 14, 2025

Jan 15, 2025

Oct 30, 2024

ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on Feb 14, 2025 going ex on Jan 15, 2025

Jan 15, 2025

Feb 14, 2025

Jan 15, 2025

Sep 06, 2024

ABBV.NB Final Cash Dividend of gross USD 1.55 paid on Nov 15, 2024 going ex on Oct 15, 2024 with reinvestment option

Oct 15, 2024

Nov 15, 2024

Oct 15, 2024

Jun 21, 2024

ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Aug 15, 2024 going ex on Jul 15, 2024 with reinvestment option

Jul 15, 2024

Aug 15, 2024

Jul 15, 2024

Feb 15, 2024

ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on May 15, 2024 going ex on Apr 12, 2024 with reinvestment option

Apr 15, 2024

May 15, 2024

Apr 12, 2024

Oct 27, 2023

ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Feb 15, 2024 going ex on Jan 12, 2024 with reinvestment option

Jan 16, 2024

Feb 15, 2024

Jan 12, 2024

Stock Splits



Date

Ex-dividend Date

Type

Ratio

No Data

Date

Ex-dividend Date

Type

Ratio

No Data

KeyAI

